Division of Nuclear Medicine, IRCCS University Hospital of Bologna, Bologna, Italy -
Division of Nuclear Medicine, IRCCS University Hospital of Bologna, Bologna, Italy.
Q J Nucl Med Mol Imaging. 2021 Dec;65(4):333-341. doi: 10.23736/S1824-4785.21.03419-1.
Prostate-specific membrane antigen (PSMA) is a molecular target for both imaging diagnostics and therapeutics, i.e., a theragnostics target. There has been a growing body of evidence supporting PSMA theragnostics approaches in the management of prostate cancer (PCa) for tailored precision medicine. Tumor characterization through PSMA-ligand PET imaging is crucial for assessing the molecular signature and eligibility for PSMA radioligand therapy. Recent U.S. Food and Drug Administration (FDA) approval of two new drug applications for PSMA PET imaging contribute to reinforce PSMA as an oncologic blockbuster. Additionally, relevant progress in the PSMA treatment has been made in the last five years. [Lu]Lu-PSMA-617 radioligand therapy for patients with progressive PSMA-avid metastatic castration-resistant PCa (mCRPC) significantly increased overall survival and radiographic progression-free survival, according to the results of an international, prospective, open label, multicenter, randomized, phase III study (VISION trial). The objective of this comprehensive review is to highlight the recent advances in PCa theragnostics, focusing on actual clinical applications and future perspectives.
前列腺特异性膜抗原（PSMA）是成像诊断和治疗的分子靶点，即治疗学靶点。越来越多的证据支持 PSMA 治疗方法在前列腺癌（PCa）的管理中的应用，以实现个性化精准医疗。通过 PSMA 配体 PET 成像进行肿瘤特征描述对于评估分子特征和 PSMA 放射性配体治疗的适应证至关重要。最近美国食品和药物管理局（FDA）批准了两项用于 PSMA PET 成像的新药申请，进一步证实了 PSMA 作为肿瘤学重磅炸弹药物的地位。此外，在过去五年中，PSMA 治疗方面也取得了相关进展。[Lu]Lu-PSMA-617 放射性配体疗法用于治疗 PSMA 阳性转移性去势抵抗性前列腺癌（mCRPC）患者，根据一项国际性、前瞻性、开放标签、多中心、随机、III 期研究（VISION 试验）的结果，显著提高了总生存期和影像学无进展生存期。本文的目的是强调 PCa 治疗学的最新进展，重点介绍实际的临床应用和未来展望。
